β-methylamino-L-alanine (BMAA) is not found in the brains of patients with confirmed Alzheimer's disease

Research output: Contribution to journalArticle

15 Citations (Scopus)
187 Downloads (Pure)

Abstract

Controversy surrounds the proposed hypothesis that exposure to β-methylamino-L-alanine (BMAA) could play a role in various neurodegenerative conditions including Alzheimer's disease (AD). Here we present the results of the most comprehensive scientific study on BMAA detection ever undertaken on brain samples from patients pathologically confirmed to have suffered from AD, and those from healthy volunteers. Following the full validation of a highly accurate and sensitive mass spectrometric method, no trace of BMAA was detected in the diseased brain or in the control specimens. This contradicts the findings of other reports and calls into question the significance of this compound in neurodegenerative disease. We have attempted to explain the potential causes of misidentification of BMAA in these studies.

Original languageEnglish
Article number36363
Number of pages9
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - 08 Nov 2016
Externally publishedYes

Fingerprint

Alanine
Alzheimer Disease
Brain
Brain Diseases
Neurodegenerative Diseases
Healthy Volunteers
beta-N-methylamino-L-alanine

Cite this

@article{2b6dbf1290704533be678c27551d89bb,
title = "β-methylamino-L-alanine (BMAA) is not found in the brains of patients with confirmed Alzheimer's disease",
abstract = "Controversy surrounds the proposed hypothesis that exposure to β-methylamino-L-alanine (BMAA) could play a role in various neurodegenerative conditions including Alzheimer's disease (AD). Here we present the results of the most comprehensive scientific study on BMAA detection ever undertaken on brain samples from patients pathologically confirmed to have suffered from AD, and those from healthy volunteers. Following the full validation of a highly accurate and sensitive mass spectrometric method, no trace of BMAA was detected in the diseased brain or in the control specimens. This contradicts the findings of other reports and calls into question the significance of this compound in neurodegenerative disease. We have attempted to explain the potential causes of misidentification of BMAA in these studies.",
author = "Meneely, {Julie P} and Chevallier, {Olivier P} and Stewart Graham and Brett Greer and Green, {Brian D} and Elliott, {Christopher T}",
year = "2016",
month = "11",
day = "8",
doi = "10.1038/srep36363",
language = "English",
volume = "6",
journal = "Nature Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - β-methylamino-L-alanine (BMAA) is not found in the brains of patients with confirmed Alzheimer's disease

AU - Meneely, Julie P

AU - Chevallier, Olivier P

AU - Graham, Stewart

AU - Greer, Brett

AU - Green, Brian D

AU - Elliott, Christopher T

PY - 2016/11/8

Y1 - 2016/11/8

N2 - Controversy surrounds the proposed hypothesis that exposure to β-methylamino-L-alanine (BMAA) could play a role in various neurodegenerative conditions including Alzheimer's disease (AD). Here we present the results of the most comprehensive scientific study on BMAA detection ever undertaken on brain samples from patients pathologically confirmed to have suffered from AD, and those from healthy volunteers. Following the full validation of a highly accurate and sensitive mass spectrometric method, no trace of BMAA was detected in the diseased brain or in the control specimens. This contradicts the findings of other reports and calls into question the significance of this compound in neurodegenerative disease. We have attempted to explain the potential causes of misidentification of BMAA in these studies.

AB - Controversy surrounds the proposed hypothesis that exposure to β-methylamino-L-alanine (BMAA) could play a role in various neurodegenerative conditions including Alzheimer's disease (AD). Here we present the results of the most comprehensive scientific study on BMAA detection ever undertaken on brain samples from patients pathologically confirmed to have suffered from AD, and those from healthy volunteers. Following the full validation of a highly accurate and sensitive mass spectrometric method, no trace of BMAA was detected in the diseased brain or in the control specimens. This contradicts the findings of other reports and calls into question the significance of this compound in neurodegenerative disease. We have attempted to explain the potential causes of misidentification of BMAA in these studies.

U2 - 10.1038/srep36363

DO - 10.1038/srep36363

M3 - Article

C2 - 27821863

VL - 6

JO - Nature Scientific Reports

JF - Nature Scientific Reports

SN - 2045-2322

M1 - 36363

ER -